Finance
Roche Q1 sales up 7% on drugs Phesgo, Vabysmo
Roche Q1 sales up 7% on drugs Phesgo, Vabysmo
Published by Global Banking and Finance Review
Posted on April 24, 2025
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair.
Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts.
Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage.
(Reporting by Ludwig Burger, Editing by Rachel More)
Related Posts
More from Finance
Explore more articles in the Finance category
UK retailers report fall in sales ahead of Christmas, CBI says
A Santa rally? Investors hope for year-end gains to cap strong 2025
S&P 500, Nasdaq futures inch up on tech rebound, Nike slumps on China pain
French authorities set new conditions on Nestle's Perrier production
Prince Harry and Meghan to revamp Archewell charitable arm
Gaza no longer in famine after aid access improves, hunger monitor says
Ukraine clinches deal to restructure $2.6 billion in 'toxic' GDP warrants
UK welcomes EU funding agreement for Ukraine
Canton Zurich urges government to soften UBS capital requirements plan
Ukraine hits Russian 'shadow fleet' tanker in Mediterranean
Explainer-How the EU's $105 billion loan to Ukraine will work without frozen Russian assets?
